Reproductive rights groups across the United States are responding to the Supreme Court’s decision to reject a challenge to how mifepristone is available.
Nancy Northup, President and CEO of the Center for Reproductive Rights said she felt “She said she was both relieved and angry about the decision. She said she was glad the decision was overturned, but she didn’t think it should have gone to the Supreme Court in the first place.
Jennifer Dalven, director of the American Civil Liberties Union The Reproductive Freedom Project warned that while today may seem like a victory for reproductive rights, “we know we are far from seeing the end of the tunnel.” Dalven said other politicians are ready to challenge abortion rights in the United States.
Destiny Lopez, Interim Co-CEO of Guttmacher Institute Lopez said the case was “based on bad faith and devoid of any factual or scientific basis.” She added that the case should never have reached the Supreme Court, echoing Northup’s sentiment. She also warned that more anti-abortion rights challenges would arise despite the outcome.
President of the American College of Obstetricians and Gynecologists Stella Dantas said the Supreme Court’s decision “provides us with much-needed relief.” She said the findings mean that “patients and clinicians across the country will continue to have access to mifepristone for medical abortion and miscarriage management.”
THE President of the American Medical Association (AMA) Bobby Mukkamala issued a statement welcoming the Supreme Court’s decision. “The effort to question the FDA’s scientific judgment and restrict access to mifepristone was based on a bogus case that was not only unfounded, but was based on speculative claims and ideological assertions,” the statement said.
Phyllis Arthur, Executive Vice President and Chief Financial Officer Health policy and programs BIO officials said they were pleased that the FDA will retain the authority to approve new drugs. “Today’s decision ensures that patients and drug developers can rely on the FDA’s rigorous approval process as the scientific and reliable standard for drug approval.”
In the meantime, DancoThe manufacturer of mifepristone, said it was pleased with the outcome of today’s decision, which “ensures access to a medicine that has been used safely and effectively for decades.” The manufacturer said it remains committed to providing safe access to abortion across the country.
This article will continue to be updated as new reactions are posted.
cnn
